Introduction {#s1}
============

Acute administration of glucagon-like peptide 1 (GLP-1) to healthy humans, and patients with type 2 diabetes, lowers blood glucose concentrations by stimulating insulin, suppressing glucagon secretion, and slowing gastric emptying ([@B1]). GLP-1 agonists have been incorporated into standard algorithms to treat hyperglycemia in patients with type 2 diabetes, and while the objective of these treatment regimens is to reduce glycemia safely ([@B2]), the importance of specifically targeting postprandial glycemia is increasingly being recognized ([@B3]). The capacity for GLP-1, and its agonists, to slow gastric emptying represents the dominant mechanism by which they reduce postprandial glycemic excursions ([@B4],[@B5]).

Long-acting GLP-1 agonists are attractive, since fewer injections are required ([@B6],[@B7]). However, there is preliminary evidence that the slowing of gastric emptying by long-acting agonists becomes attenuated over time ([@B6],[@B8]--[@B10]), although only one study has hitherto examined directly whether sustained GLP-1 receptor activation induces tachyphylaxis for the effects of GLP-1 on gastric emptying ([@B11]). In this study, the delay in gastric emptying of a liquid meal was reported to be diminished after administration of intravenous GLP-1 for 270 min compared with 30 min ([@B11]), but methodological limitations included the use of a suboptimal dye dilution technique to quantify gastric emptying and the provision of a second meal only 4 h after the first, with potential for incomplete emptying of the first meal or ongoing nutrient stimulation of the small intestine to influence the disposition of the second meal. Furthermore, this previous study did not evaluate the effect of intermittent GLP-1 receptor stimulation, which is of substantial clinical relevance.

We undertook the current study to determine accurately whether tachyphylaxis to the effect of GLP-1 on gastric emptying occurs rapidly and affects postprandial glycemia. The primary hypothesis was that intermittent administration of GLP-1 would slow gastric emptying more than prolonged continuous administration. Secondary hypotheses were that *1*) prolonged infusion of GLP-1 would still slow gastric emptying compared with placebo, *2*) the effects of intermittent and acute GLP-1 infusions on gastric emptying would be similar, and *3*) postprandial glycemic excursions would be related to the rate of gastric emptying.

Research Design and Methods {#s2}
===========================

Healthy men aged 18--35 years were eligible, and those with diabetes (HbA~1c~ \>6.0% or 42.1 mmol/mol), impaired renal function or anemia, currently smoking, consuming \>20 g/day alcohol, receiving medication known to affect gastrointestinal motility or glycemia, or with a history of gastric or small intestinal surgery were excluded.

Each subject attended the hospital after an overnight fast on two occasions separated by at least 4 days to be studied under regimens A and B in a randomized, double-blind fashion. Randomization was carried out by the Royal Adelaide Hospital Pharmacy using a Web-based program. Allocation concealment was maintained throughout. An intravenous catheter was inserted into each arm for drug delivery and blood sampling. Gastric emptying was measured at approximately the same time of day in each subject. During study visits, energy intake was standardized and subjects remained sitting or lying, unless toileting. GLP-1 (7--36)amide (Bachem, Germany) was infused at a rate of 0.8 pmol/kg/min, which is known to result in receptor stimulation representative of pharmacological agents ([@B11]). Placebo was 0.9% sodium chloride, and all study drugs were infused at 1 mL/min.

Regimen A {#s3}
---------

Subjects received an intravenous infusion of GLP-1 for 4.5 h followed by 19.5 h of placebo and, finally, 4.5 h of GLP-1. The response to "intermittent" GLP-1 was assessed during the second GLP-1 infusion ([Fig. 1](#F1){ref-type="fig"}).

![Study protocol. Scintigraphic measurements of gastric emptying were performed over 4 h both from *T* = 0 h to *T* = 4 h and *T* = 24 h to *T* = 28 h. Infusion of study drug was commenced 30 min prior to ingestion of meal to allow for plasma concentrations to reach steady-state.](785fig1){#F1}

Regimen B {#s4}
---------

Subjects received a 4.5-h intravenous infusion of placebo followed by 24 h of GLP-1. The effect of "prolonged" GLP-1 exposure was assessed after 20 h of GLP-1 infusion ([Fig. 1](#F1){ref-type="fig"}). The study protocol was approved by the Royal Adelaide Hospital Research Ethics Committee and registered as a clinical trial. Written informed consent was obtained from the subjects.

Gastric Emptying {#s5}
----------------

Radioisotopic data were acquired with the subjects seated with their back against a γ camera (GE Healthcare). On four occasions ([Fig. 1](#F1){ref-type="fig"}), subjects ingested a test meal comprising 65 g powdered mashed potato (Deb Instant; Continental, Sydney, Australia), 45 g margarine (Flora Original; Unilever, Sydney, Australia), 20 g glucose, and 200 mL water, labeled with 20 MBq ^99m^Tc-calcium-phytate colloid. The meal contained 2,687 kJ (642 kcal), with 72.3 g carbohydrate, 35.5 g fat, and 8.1 g protein. Scintigraphic images were acquired every minute for the first hour and then at 3-min intervals for a further 3 h. A left lateral image of the stomach was acquired to correct for γ-ray attenuation ([@B12]). Data were also corrected for radioactive decay and subject movement. A region of interest was drawn around the total stomach, and percent retention was determined at 0, 30, 60, 90, 120, 150, 210, and 240 min. The time taken for the stomach to empty 50% (T50) was also calculated ([@B12]).

Blood Glucose and Insulin {#s6}
-------------------------

Blood glucose concentrations were measured using a blood gas analyzer (ABL800 Flex; Radiometer Medical, Brønshøj, Denmark), and serum insulin was measured by ELISA (Mercodia) ([@B13]). Blood was sampled at −30, 0, 30, 60, 90, 120, and 180 min.

Statistical Analysis {#s7}
--------------------

Data are presented as mean (95% CI). Area under the blood glucose curve (AUC) was derived using the trapezoidal rule. The sample size was calculated using SD of 25% around the mean gastric emptying of a similar meal ([@B14]), with an anticipated reduction in gastric slowing during prolonged GLP-1 administration of 50% ([@B11]). Allowing for 10% greater margins, at least nine subjects were required (β = 0.8, α = 0.05); therefore, we studied 10 subjects.

A mixed-effects maximum likelihood model, with infusion as a fixed effect, was used to determine differences between infusions. If an effect was present, post hoc pairwise analysis was conducted between infusions, with Bonferonni corrections for repeated testing. *P* values \<0.05 were considered significant.

Because after a similar meal we have previously reported *1*) strong associations between glycemic excursions during the initial 60 min and the rate of gastric emptying ([@B14]) and *2*) serum insulin concentrations markedly elevated for 180 min, glycemia was calculated as AUC~60~ and insulinemia as AUC~180~. The relationships between gastric emptying, glycemia, and insulinemia were determined using univariate analysis, with correction for within-subject correlations ([@B15]).

Results {#s8}
=======

Ten healthy male subjects (age 24 \[95% CI 23--25\] years, BMI 25 \[22--27\] kg/m^2^) completed the study without any adverse effects.

Gastric Emptying {#s9}
----------------

All GLP-1 infusions slowed gastric emptying compared with placebo (*P* \< 0.001) ([Fig. 2](#F2){ref-type="fig"}). Acute GLP-1 compared with placebo increased intragastric retention (*P* = 0.001), as did intermittent compared with prolonged infusion (*P* = 0.04) ([Fig. 2](#F2){ref-type="fig"}). While prolonged infusion increased retention in comparison with placebo (*P* = 0.003), acute and intermittent infusions had similar effects (*P* = 1.0) ([Fig. 2](#F2){ref-type="fig"}). T50 was affected by the study infusion (*P* = 0.01), with acute infusion (143 min \[104--183\] min) delaying the T50 compared with placebo (79 min \[65--94\]); *P* = 0.02) and a trend for intermittent (168 min \[109--225\]) to delay compared with prolonged (122 min \[75--170\]; *P* = 0.09). However, there was no significant difference in T50 between prolonged and placebo (*P* = 0.26) or acute and intermittent (*P* = 0.69) infusions.

![The effect of different GLP-1 regimens on gastric emptying. There was an effect between the various infusions (*P* \< 0.001). Acute GLP-1 compared with placebo increased intragastric retention (*P* = 0.001), as did intermittent compared with prolonged infusion (*P* = 0.04). While prolonged infusion increased retention in comparison with placebo (*P* = 0.003), acute and intermittent infusions had similar effects (*P* = 1.0). Data are mean ± SEM. A mixed-effects maximum likelihood model was used to determine differences with post hoc testing adjusted for multiple comparisons.](785fig2){#F2}

Blood Glucose and Serum Insulin {#s10}
-------------------------------

There was a small, but statistically significant, difference in fasting blood glucose concentrations prior to saline or GLP-1 infusions (*T* = −30: placebo 5.5 mmol/L \[5.2--5.7\] vs. acute 5.0 mmol/L \[4.7--5.3\]; *P* \< 0.001). Postprandial glycemia (AUC~60~) was affected by the infusion (*P* \< 0.001) ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0893/-/DC1)). Acute GLP-1 reduced postprandial glycemia (AUC~60~) compared with placebo (*P* = 0.001), as did intermittent compared with prolonged (*P* = 0.007), but there was no difference between prolonged and placebo (*P* = 0.21) or acute and intermittent (*P* = 1.0) regimens ([Fig. 3*A*](#F3){ref-type="fig"}). The peak blood glucose concentration was affected by the infusion (*P* \< 0.001), being greater during placebo 7.1 mmol/L (6.4--7.7) than either acute (5.8 mmol/L \[5.4--6.3\]), intermittent (6.0 mmol/L \[5.5--6.4\]), or prolonged (6.6 mmol/L \[6.1--7.2\]) GLP-1 infusions.

![The effect of different GLP-1 regimens on postprandial glycemia and insulinemia. *A*: There was an effect between infusions (*P* \< 0.001). Acute GLP-1 reduced postprandial glycemia (AUC~0--60~) compared with placebo (\**P* = 0.001), as did intermittent compared with prolonged (\#*P* = 0.007), but there was no difference between prolonged and placebo (*P* = 0.21) or acute and intermittent (*P* = 1.0) regimens. *B*: There was an effect between the various infusions (*P* \< 0.001). Postprandial insulin concentrations were reduced during intermittent compared with prolonged infusion (\**P* = 0.003); comparing acute infusion with placebo, the difference was not statistically significant (*P* = 0.07). Postprandial insulin concentrations were comparable between acute and intermittent infusions (*P* = 1.0) and between prolonged infusion and placebo (*P* = 0.21). Data are mean ± SEM. A mixed-effects maximum likelihood model was used to determine differences with post hoc testing adjusted for multiple comparisons. IV, intravenous.](785fig3){#F3}

Fasting insulin concentrations were similar \[*T* = −30: placebo (5 mU/L \[4--6\]) vs. acute (5 mU/L \[3--6\]; *P* = 0.15)\]. Overall insulin secretion was affected by the study infusion (*P* \< 0.001) ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0893/-/DC1)). Postprandial insulin concentrations were reduced during intermittent compared with prolonged infusion (*P* = 0.003), but there was no statistically significant difference between acute GLP-1 and placebo (*P* = 0.07) ([Fig. 3*B*](#F3){ref-type="fig"}). Postprandial insulin concentrations were comparable between acute and intermittent infusions (*P* = 1.0) and between prolonged infusion and placebo (*P* = 0.85) ([Fig. 3*B*](#F3){ref-type="fig"}).

Peak insulin concentrations were also affected (*P* = 0.003), with secretion less during acute (25.1 mU/L \[16.4--33.8\]) than placebo (39.8 mU/L \[31.9--47.6\]), *P* = 0.03, and less during intermittent (21.0 mU/L \[14.6--27.4 when compared with prolonged (43.0 mU/L \[28.0--58.0\]), *P* = 0.03. However, peak insulin concentrations were similar between prolonged and placebo and between acute and intermittent (*P* = 1.0 for both). The insulin-to-glucose ratios (AUC~180~) were similarly affected. Due to slower emptying, the ratios were less with acute than placebo (*P* = 0.035) and intermittent compared with prolonged (*P* = 0.002) ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0893/-/DC1)).

Relationship Between Gastric Emptying, Postprandial Glycemia, and Insulinemia {#s11}
-----------------------------------------------------------------------------

There were strong associations between gastric emptying and postprandial glycemia (AUC~60~: *r* = −0.49; *P* = 0.005) ([Fig. 4*A*](#F4){ref-type="fig"}) and between gastric emptying and insulinemia (AUC~240~: *r* = −0.41; *P* = 0.02 \[[Fig. 4*B*](#F4){ref-type="fig"}\] and % gastric retention AUC~60~ vs. insulin peak: *r* = −0.46; *P* = 0.01), so that when gastric emptying was faster, glycemic and insulin excursions were greater.

![Correlation between gastric emptying, glycemia, and insulinemia. The rate of gastric emptying (% gastric retention AUC~60~) was closely associated with postprandial glycemia (AUC~60~: *r* = −0.49; *P* = 0.005) (*A*) and postprandial insulinemia (AUC~180~: *r* = −0.41; *P* = 0.02) (*B*). Data are correlated within subject ([@B15]).](785fig4){#F4}

Discussion {#s12}
==========

This study establishes that while acute, intermittent, and prolonged infusions of exogenous GLP-1 all slow gastric emptying substantially in health, the magnitude of this effect is attenuated during prolonged stimulation, which reduces the effect of GLP-1 on postprandial glycemic excursions.

These observations were anticipated and are consistent with the notion that short-acting agonists appear to have a substantial, and sustained, effect to slow gastric emptying, whereas the acute effects of long-acting agonists on gastric emptying diminish with ongoing use ([@B6],[@B9],[@B10],[@B16]). Indeed, while prolonged stimulation with exenatide once a week lowers postprandial glycemia, the magnitude of lowering is greater when exenatide twice daily is administered ([@B6]).

While a similar effect on gastric emptying was suggested by both Nauck et al. ([@B11]) and Näslund et al. ([@B8]) there were limitations with both studies. In both studies, the methods used to measuring measure gastric emptying were less than optimal and, in the former study, were also confounded by potential order effects, while in the latter study intermittent stimulation was achieved using suprapharmacological bolus dosing. However, building on these previous observations ([@B8],[@B11]), our data establish unequivocally that tachyphylaxis to the gastric motor effects of GLP-1 occurs. Moreover, our study design allowed us not only to compare the effects of continuous and intermittent GLP-1 receptor stimulation at plasma concentrations that are similar to plasma concentrations achieved during standard dosing with commercially available short and long-acting GLP-1 agonists ([@B6],[@B11],[@B16],[@B17]) but also to evaluate its impact on postprandial glycemia, which indicates that this phenomenon is clinically relevant.

It should be recognized that with prolonged (\~24 h) GLP-1 receptor stimulation, the slowing of gastric emptying compared with placebo was attenuated but not abolished. This is important given that even modest changes in gastric emptying have the potential to affect postprandial glycemia substantially in patients with diabetes ([@B18]). It remains to be determined whether effects on gastric emptying would be further attenuated with receptor stimulation beyond 24 h.

It remains uncertain why there is tachyphylaxis to the effect of GLP-1 to slow gastric emptying and not to the islet cell effects, but there is limited evidence to suggest a role for vagal pathways ([@B11]). It should be recognized that the test meal had a substantial carbohydrate and calorie content and that potentially the magnitude of attenuation of the slowing of gastric emptying by exogenous GLP-1 may be influenced by meal composition ([@B14],[@B19]). Other potential limitations are that we chose to study healthy volunteers in order to minimize potential confounding by marked hyperglycemia (which is itself known to slow gastric emptying) ([@B20]), autonomic neuropathy (which may influence the effects of GLP-1 on the proximal stomach) ([@B21]), and the potential for abnormally slow gastric emptying at baseline ([@B22],[@B23]). The latter variable may be particularly important, as the capacity for GLP-1 to slow gastric emptying is dependent on the underlying rate of emptying ([@B5]). Aside from these factors, it is anticipated that patients with type 2 diabetes would respond similarly to healthy subjects, but this is not assured ([@B2],[@B6],[@B7],[@B24]).

The clinical relevance of our study will require confirmatory studies comparing GLP-1 agonists in type 2 patients that have problematic postprandial glycemic excursions, particularly in those with normal, or rapid, gastric emptying. While long-acting agonists may have greater potency to reduce HbA~1c~ in unselected patients with type 2 diabetes ([@B6],[@B25]), the use of an isotope breath test to measure gastric emptying has the potential to determine whether short-acting agonists may be more appropriate for a particular patient ([@B16]). Such an approach would, however, need to evaluate postprandial effects against any potential worsening of preprandial glycemia ([@B26]).

In conclusion, there is a marked attenuation of the magnitude of slowing of gastric emptying with prolonged compared with intermittent stimulation of the GLP-1 receptor in health, supporting the concept of rapid tachyphylaxis. Moreover, the reduction in postprandial glycemia induced by GLP-1 is dependent on the magnitude of slowing of emptying. These data suggest that the choice of GLP-1 agonist for a given patient should be based on the relative importance of targeting postprandial glycemia for an individual patient.

Supplementary Material
======================

###### Supplementary Data

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0893/-/DC1>.

See accompanying commentary, p. 407.
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